These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23416532)

  • 21. Inconvenient truth: cancer biomarker development by using proteomics.
    Kondo T
    Biochim Biophys Acta; 2014 May; 1844(5):861-5. PubMed ID: 23896458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers Found in the Tumor Interstitial Fluid may Help Explain the Differential Behavior Among Keratinocyte Carcinomas.
    Matas-Nadal C; Bech-Serra JJ; Gatius S; Gomez X; Ribes-Santolaria M; Guasch-Vallés M; Pedraza N; Casanova JM; de la Torre Gómez C; Garí E; Aguayo-Ortiz RS
    Mol Cell Proteomics; 2023 Jun; 22(6):100547. PubMed ID: 37059366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-secreted signals shape lymphoma identity.
    Gloghini A; Bongarzone I
    Semin Cancer Biol; 2015 Oct; 34():81-91. PubMed ID: 25837156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow.
    Brunoro GVF; Carvalho PC; Barbosa VC; Pagnoncelli D; De Moura Gallo CV; Perales J; Zahedi RP; Valente RH; Neves-Ferreira AGDC
    BMC Cancer; 2019 Apr; 19(1):365. PubMed ID: 30999875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fascin is a circulating tumor marker for head and neck cancer as determined by a proteomic analysis of interstitial fluid from the tumor microenvironment.
    Lee LY; Chen YJ; Lu YC; Liao CT; Chen IH; Chang JT; Huang YC; Chen WH; Huang CC; Tsai CY; Cheng AJ
    Clin Chem Lab Med; 2015 Sep; 53(10):1631-41. PubMed ID: 25781684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: its diagnostic and prognostic values. A review.
    Kotyza J
    Int J Biol Markers; 2012 Oct; 27(3):169-78. PubMed ID: 22610755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives.
    Fontana S; Saieva L; Taverna S; Alessandro R
    Proteomics; 2013 May; 13(10-11):1581-94. PubMed ID: 23401131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.
    Terkelsen T; Haakensen VD; Saldova R; Gromov P; Hansen MK; Stöckmann H; Lingjaerde OC; Børresen-Dale AL; Papaleo E; Helland Å; Rudd PM; Gromova I
    Mol Oncol; 2018 Jun; 12(6):972-990. PubMed ID: 29698574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and opportunities for cell line secretomes in cancer proteomics.
    Méndez O; Villanueva J
    Proteomics Clin Appl; 2015 Apr; 9(3-4):348-57. PubMed ID: 25418557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the endogenous peptidomes of cancer for biomarkers: A new endeavor.
    Lee PY; Low TY; Jamal R
    Adv Clin Chem; 2019; 88():67-89. PubMed ID: 30612607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gastric fluid proteome as a potential source of gastric cancer biomarkers.
    Wu W; Chung MC
    J Proteomics; 2013 Sep; 90():3-13. PubMed ID: 23665003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis.
    Baronzio G; Schwartz L; Kiselevsky M; Guais A; Sanders E; Milanesi G; Baronzio M; Freitas I
    Anticancer Res; 2012 Feb; 32(2):405-14. PubMed ID: 22287726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in proximal fluid proteomics for disease biomarker discovery.
    Teng PN; Bateman NW; Hood BL; Conrads TP
    J Proteome Res; 2010 Dec; 9(12):6091-100. PubMed ID: 21028795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment.
    Greening DW; Kapp EA; Ji H; Speed TP; Simpson RJ
    Biochim Biophys Acta; 2013 Nov; 1834(11):2396-407. PubMed ID: 23684732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probing the colorectal cancer proteome for biomarkers: Current status and perspectives.
    Lee PY; Chin SF; Low TY; Jamal R
    J Proteomics; 2018 Sep; 187():93-105. PubMed ID: 29953962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The secretome in cancer progression.
    Paltridge JL; Belle L; Khew-Goodall Y
    Biochim Biophys Acta; 2013 Nov; 1834(11):2233-41. PubMed ID: 23542208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The human secretome atlas initiative: implications in health and disease conditions.
    Brown KJ; Seol H; Pillai DK; Sankoorikal BJ; Formolo CA; Mac J; Edwards NJ; Rose MC; Hathout Y
    Biochim Biophys Acta; 2013 Nov; 1834(11):2454-61. PubMed ID: 23603790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic approaches to decipher cancer cell secretome.
    Brandi J; Manfredi M; Speziali G; Gosetti F; Marengo E; Cecconi D
    Semin Cell Dev Biol; 2018 Jun; 78():93-101. PubMed ID: 28684183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research.
    Tyanova S; Cox J
    Methods Mol Biol; 2018; 1711():133-148. PubMed ID: 29344888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of oncoproteomics to cancer biomarker discovery.
    Cho WC
    Mol Cancer; 2007 Apr; 6():25. PubMed ID: 17407558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.